{"id":2092,"date":"2022-09-12T08:32:37","date_gmt":"2022-09-12T08:32:37","guid":{"rendered":"https:\/\/neuropediatoolbox.org\/?p=2092"},"modified":"2026-08-11T10:17:21","modified_gmt":"2026-08-11T10:17:21","slug":"palivizumab-en-ninos-con-enfermedades-neurologicas","status":"publish","type":"post","link":"https:\/\/neuropediatoolkit.org\/en\/palivizumab-en-ninos-con-enfermedades-neurologicas\/","title":{"rendered":"RSV prophylaxis in children with neurological diseases."},"content":{"rendered":"<p class=\"wp-block-paragraph\">Prophylaxis with nirsevimab is recommended for the prevention of severe lower respiratory tract diseases caused by RSV, during periods of expected risk of RSV infection, in:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Patients under 24 months of age affected by neuromuscular diseases with marked hypotonia and\/or respiratory muscle weakness. <\/li>\n\n\n\n<li>Patients under 24 months of age affected by static or<br>chromosomal diseases presenting with marked hypotonia (e.g., Prader-Willi syndrome). <\/li>\n<\/ul>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/neuropediatoolkit.org\/wp-content\/uploads\/2022\/09\/nirsevimab-infov2-sep2025.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of nirsevimab-infov2-sep2025.\"><\/object><a id=\"wp-block-file--media-22fd4c1b-a67d-477d-a8b2-c3d53671d872\" href=\"https:\/\/neuropediatoolkit.org\/wp-content\/uploads\/2022\/09\/nirsevimab-infov2-sep2025.pdf\">nirsevimab-infov2-sep2025<\/a><a href=\"https:\/\/neuropediatoolkit.org\/wp-content\/uploads\/2022\/09\/nirsevimab-infov2-sep2025.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-22fd4c1b-a67d-477d-a8b2-c3d53671d872\">Download<\/a><\/div>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/neuropediatoolkit.org\/wp-content\/uploads\/2022\/09\/NirsevimabActualizacion.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of NirsevimabActualizacion.\"><\/object><a id=\"wp-block-file--media-05eb5b09-7881-4d43-ba5a-2addfb0966ca\" href=\"https:\/\/neuropediatoolkit.org\/wp-content\/uploads\/2022\/09\/NirsevimabActualizacion.pdf\">NirsevimabUpdate<\/a><a href=\"https:\/\/neuropediatoolkit.org\/wp-content\/uploads\/2022\/09\/NirsevimabActualizacion.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-05eb5b09-7881-4d43-ba5a-2addfb0966ca\">Download<\/a><\/div>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/neuropediatoolkit.org\/wp-content\/uploads\/2022\/09\/RECOMENDACIONES_SENEP_uso_PALIVIZUMAB_corregido_por_AE_con_logos.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of RECOMENDACIONES_SENEP_uso_PALIVIZUMAB_corregido_por_AE_con_logos.\"><\/object><a id=\"wp-block-file--media-53309992-92a1-4516-a3d2-9bbb5f918a81\" href=\"https:\/\/neuropediatoolkit.org\/wp-content\/uploads\/2022\/09\/RECOMENDACIONES_SENEP_uso_PALIVIZUMAB_corregido_por_AE_con_logos.pdf\">RECOMENDACIONES_SENEP_uso_PALIVIZUMAB_corregido_por_AE_con_logos<\/a><a href=\"https:\/\/neuropediatoolkit.org\/wp-content\/uploads\/2022\/09\/RECOMENDACIONES_SENEP_uso_PALIVIZUMAB_corregido_por_AE_con_logos.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-53309992-92a1-4516-a3d2-9bbb5f918a81\">Download<\/a><\/div>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>","protected":false},"excerpt":{"rendered":"<p>Prophylaxis with nirsevimab is recommended for the prevention of severe lower respiratory tract diseases caused by RSV, during periods of expected risk of RSV infection, in:<\/p>","protected":false},"author":1,"featured_media":2096,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_themeisle_gutenberg_block_has_review":false,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-2092","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-aspectos-pediatricos","entry"],"_links":{"self":[{"href":"https:\/\/neuropediatoolkit.org\/en\/wp-json\/wp\/v2\/posts\/2092","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/neuropediatoolkit.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/neuropediatoolkit.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/neuropediatoolkit.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/neuropediatoolkit.org\/en\/wp-json\/wp\/v2\/comments?post=2092"}],"version-history":[{"count":4,"href":"https:\/\/neuropediatoolkit.org\/en\/wp-json\/wp\/v2\/posts\/2092\/revisions"}],"predecessor-version":[{"id":8507,"href":"https:\/\/neuropediatoolkit.org\/en\/wp-json\/wp\/v2\/posts\/2092\/revisions\/8507"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/neuropediatoolkit.org\/en\/wp-json\/wp\/v2\/media\/2096"}],"wp:attachment":[{"href":"https:\/\/neuropediatoolkit.org\/en\/wp-json\/wp\/v2\/media?parent=2092"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/neuropediatoolkit.org\/en\/wp-json\/wp\/v2\/categories?post=2092"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/neuropediatoolkit.org\/en\/wp-json\/wp\/v2\/tags?post=2092"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}